IXC 5.71% 7.4¢ invex therapeutics ltd

Ann: Phase III Clinical Trial Update and New IIH Market Analysis, page-109

  1. 795 Posts.
    lightbulb Created with Sketch. 45
    I could eat my words here, but I really don't think ozempic is relevant here. It hasn't been shown to reduce ICP and presendin hasn't been shown to aid in weight loss. The issue in my opinion is lumbar puncture and the prospect of being on a placebo for 24 weeks. Coupled with the currently rigorous diagnostic criteria to admit patients as I said a few days ago. If management decides to half the trial size and admit a wider variety of patients *hopefully* it will still show efficacy
 
watchlist Created with Sketch. Add IXC (ASX) to my watchlist
(20min delay)
Last
7.4¢
Change
0.004(5.71%)
Mkt cap ! $5.561M
Open High Low Value Volume
7.1¢ 7.5¢ 7.1¢ $4.091K 54.95K

Buyers (Bids)

No. Vol. Price($)
1 198734 7.0¢
 

Sellers (Offers)

Price($) Vol. No.
7.4¢ 29802 1
View Market Depth
Last trade - 16.10pm 21/06/2024 (20 minute delay) ?
IXC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.